12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Performance fees in UCITS and certain types of AIFs: ESMA guidelines - The European Securities and ...
Read More >
For employers wishing to train employees using computer-based, online programs, OSHA recently reiter...
Read More >
On January 28, 2020, Senator Lindey Tippins introduced Georgia Senate Bill 315 (the “Lien Bill”), ...
Read More >
The majority of middle-market M&A has followed a similar structure for quite some time: while ensuri...
Read More >
In New York, 2020 will be the last year employers who employ tipped employees in car washes, nail sa...
Read More >
Seyfarth Synopsis: The federal Drug Enforcement Agency (DEA) recently announced that drugs that incl...
Read More >